Cleveland Clinic Taussig Cancer Institute

Taussig Cancer Institute is the hub for Cleveland Clinic Cancer Center.


 

Nivo +/- Ipi, or Pembro Recommended as 2nd Line for mCRC, Trials on IO vs. Chemo or + Chemo Are Underway for MSI-High mCRC and Adjuvant, Ragorafenib + Nivo Resulted in 36% RR in MSS Disease

1,403 views
December 10, 2019
0 Comments
Login to view comments. Click here to Login